Arovella Reports Tumour Clearance in Gastric Cancer Animal Study, Backs Faster FDA Engagement
ALA: $0.051 +0.00% · MC: $60M
Arovella Therapeutics reported that its ALA-105 cell therapy cleared tumours in five of seven animals in a gastric cancer study, while all animals in a smaller group receiving an IL-12-armoured version survived the study with tumours eliminated; no control animals survived. The board supports advancing the program to at-scale manufacturing and seeking formal FDA engagement early next year, although the results are from an animal study.

Comments